The treatment landscape for ATTR amyloidosis is changing. And clinicians can potentially look forward to having more treatment options for their patients through ongoing studies that use strategies for reducing the production of transthyretin (TTR) protein. To hear more, join Dr. Marianna Fontana, Director of the UCL CMR unit at the Royal Free Hospital. She is Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, Division of Medicine, University College London, UK.
Transformation of Treatment Strategies for ATTR Amyloidosis
Share
Save
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Recommended
Details
Overview
The treatment landscape for ATTR amyloidosis is changing. And clinicians can potentially look forward to having more treatment options for their patients through ongoing studies that use strategies for reducing the production of transthyretin (TTR) protein. To hear more, join Dr. Marianna Fontana, Director of the UCL CMR unit at the Royal Free Hospital. She is Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, Division of Medicine, University College London, UK.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?